These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 28420003)

  • 1. Retrospective Analysis of the Risk Factors for Grade IV Neutropenia in Oesophageal Cancer Patients Treated with a Docetaxel, Cisplatin, and 5-Fluorouracil Regimen.
    Naito M; Yamamoto T; Shimamoto C; Miwa Y
    Chemotherapy; 2017; 62(4):215-224. PubMed ID: 28420003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma.
    Katada C; Sugawara M; Hara H; Fujii H; Nakajima TE; Ando T; Kojima T; Watanabe A; Sakamoto Y; Ishikawa H; Hosokawa A; Hamamoto Y; Muto M; Tahara M; Koizumi W
    Jpn J Clin Oncol; 2021 Feb; 51(2):199-204. PubMed ID: 33147611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma.
    Tanaka Y; Yoshida K; Yamada A; Tanahashi T; Okumura N; Matsuhashi N; Yamaguchi K; Miyazaki T
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1143-52. PubMed ID: 26896963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer.
    Yokota T; Hatooka S; Ura T; Abe T; Takahari D; Shitara K; Nomura M; Kondo C; Mizota A; Yatabe Y; Shinoda M; Muro K
    Anticancer Res; 2011 Oct; 31(10):3535-41. PubMed ID: 21965775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer.
    Huang CE; Lu CH; Chen PT; Chan CH; Chen WC; Wang WH; Wu JY; Kuan FC; Lee KD; Chen CC
    J Clin Pharm Ther; 2012 Jun; 37(3):342-7. PubMed ID: 21950487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of biweekly chemotherapy with docetaxel and cisplatin in high-risk patients with unresectable non-small cell lung cancer.
    Kim MJ; Kim SH; Kang JH; Kim HG; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim MG; Choi JY; Lee GW
    Chemotherapy; 2013; 59(3):159-66. PubMed ID: 24107481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility study.
    Maeda O; Matsuoka A; Miyahara R; Funasaka K; Hirooka Y; Fukaya M; Nagino M; Kodera Y; Goto H; Ando Y
    World J Gastroenterol; 2017 Feb; 23(6):1090-1097. PubMed ID: 28246483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective analysis of severe neutropenia in patients receiving concomitant administration of docetaxel and clarithromycin.
    Tsuji D; Kamezato M; Daimon T; Taku K; Hatori M; Ikeda M; Hayashi H; Inoue K; Eto T; Itoh K
    Chemotherapy; 2013; 59(6):407-13. PubMed ID: 25011542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.
    Shim HJ; Cho SH; Hwang JE; Bae WK; Song SY; Cho SB; Lee WS; Joo YE; Na KJ; Chung IJ
    Am J Clin Oncol; 2010 Dec; 33(6):624-8. PubMed ID: 20142726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Response of Esophageal Cancer to Neoadjuvant Chemotherapy with Docetaxel-Cisplatin-5-Fluorouracil Represents Sensitivity: A Phase II Study.
    Matsumoto A; Nishikawa K; Yuda M; Tanaka Y; Tanishima Y; Arakawa Y; Ishibashi Y; Sakuyama T; Omura N; Mitsumori N; Aiba K; Yanaga K
    Anticancer Res; 2016 Apr; 36(4):1937-42. PubMed ID: 27069183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to docetaxel and cisplatin induction chemotherapy of locally advanced head and neck squamous cell carcinoma: a multicenter, non-comparative, open-label interventional pilot study.
    Noronha V; Goswami C; Patil S; Joshi A; Patil VM; Murthy V; Arya S; Juvekar S; Goud S; Prabhash K
    J Laryngol Otol; 2016 Sep; 130(9):833-42. PubMed ID: 27456399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer.
    Quintero-Aldana G; Jorge M; Grande C; Salgado M; Gallardo E; Varela S; López C; Villanueva MJ; Fernández A; Alvarez E; González P; Castellanos J; Casal J; López R; Campos Balea B
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):731-7. PubMed ID: 26242221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma.
    Honda M; Miura A; Izumi Y; Kato T; Ryotokuji T; Monma K; Fujiwara J; Egashira H; Nemoto T
    Dis Esophagus; 2010 Nov; 23(8):641-5. PubMed ID: 20545978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil for patients with node-positive esophageal cancer.
    Watanabe M; Nagai Y; Kinoshita K; Saito S; Kurashige J; Karashima R; Hirashima K; Sato N; Imamura Y; Hiyoshi Y; Baba Y; Iwagami S; Miyamoto Y; Iwatsuki M; Hayashi N; Baba H
    Digestion; 2011; 83(3):146-52. PubMed ID: 21266808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study.
    Driessen CM; de Boer JP; Gelderblom H; Rasch CR; de Jong MA; Verbist BM; Melchers WJ; Tesselaar ME; van der Graaf WT; Kaanders JH; van Herpen CM
    Eur J Cancer; 2016 Jan; 52():77-84. PubMed ID: 26655558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of effect of SLC22A2 genotype on cisplatin-induced nephrotoxicity in oesophageal cancer patients receiving cisplatin and 5-fluorouracil: report of results discordant with those of earlier studies.
    Hinai Y; Motoyama S; Niioka T; Miura M
    J Clin Pharm Ther; 2013 Dec; 38(6):498-503. PubMed ID: 24102360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I dose-escalating study of 24-h continuous infusion of 5-fluorouracil in combination with weekly docetaxel and cisplatin in patients with advanced gastric cancer.
    Wang B; Zhang W; Hong X; Guo Y; Li J
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):213-8. PubMed ID: 18343924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.
    Di Bartolomeo M; Buzzoni R; Mariani L; Ferrario E; Katia D; Gevorgyan A; Zilembo N; Bordonaro R; Bochicchio AM; Massidda B; Ardizzoia A; Marini G; Aitini E; Schieppati G; Comella G; Pinotti G; Palazzo S; Cicero G; Bajetta E; ; Villa E; Fagnani D; Reguzzoni G; Agostana B; Oliani C; Kildani B; Duro M; Botta M; Mozzana R; Mantovani G
    Oncology; 2006; 71(5-6):341-6. PubMed ID: 17855795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tract.
    Ilhan-Mutlu A; Preusser M; Schoppmann SF; Asari R; Ba-Ssalamah A; Schwameis K; Pluschnig U; Birner P; Püspök A; Zacherl J; Hejna M
    Anticancer Res; 2013 Aug; 33(8):3455-9. PubMed ID: 23898119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501).
    Higuchi K; Koizumi W; Tanabe S; Sasaki T; Katada C; Ishiyama H; Hayakawa K
    Radiother Oncol; 2008 Jun; 87(3):398-404. PubMed ID: 18405987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.